Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $804.6957.

Several equities analysts have commented on the stock. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Oppenheimer reiterated an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Piper Sandler assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price target on the stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $760.27 on Wednesday. The firm has a market capitalization of $80.38 billion, a P/E ratio of 18.29, a P/E/G ratio of 2.02 and a beta of 0.40. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $766.41 and its two-hundred day moving average is $717.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $12.07 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,774 shares of company stock worth $2,942,738 over the last three months. Insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the business. WPG Advisers LLC grew its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $27,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $31,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.